Genetic ablation or pharmacological inhibitors of NLRP3 or ASC and caspase-1 improve glucose tolerance and insulin sensitivity in HFD-fed mice and prevent post-MI cardiac enlargement and limit infarct size [4,68,70,71]. The gene discussed is NLRP3; the disease is myocardial infarction.